

ACARE LevelUp MAGAZINE



WWW.GA2LEN-ACARE.COM

February 1, 2024

Content

New centers

Current event

- Preceptorship Abu Dhabi

Past event

- ACARE at the UCARE Conference 2023

Educational Activities

- ACARE LevelUP Webinar 1
- Make a Difference 9, 10 and 11
- Podcast All Things Angioedema
- Journal Club

Feature

- Hot Topics in Angioedema by Dr. Jason Fok
- Hereditary angioedema in India: Progress and lessons learned by Dr. Ankur Jindal and Prof. Sunil Dogra
- HAEi and You!

Current and Upcoming Scientific Projects:
We need YOUR participation

Top News

Articles by Physicians from
ACARE network

Insights from HAEi by
Rachel Annals

Upcoming educational webinars



GA²LEN UCARE Conference 2023

New Centers

It is our great pleasure to welcome the following centers to the ACARE family:

DATE OF JOINING	NAME OF CENTER	COUNTRY
30.10.2023	Centro Hospitalar Vila Nova De Gaia	Italy
10.11.2023	Sacco University Hospital Milan	Italy
15.11.2023	University Hospital "Attikon"	Greece
16.11.2023	Naval Hospital of Athens	Greece
17.11.2023	Respiralab Research Group	Ecuador
12.12.2023	Tehran University of Medical Sciences	Iran
22.01.2024	IRCCS Istituti Clinici Scientifici Maugeri Milano, Ambulatorio Angioedema	Italy

You can find more information on our ACARE centers [here](#).

ACARE CENTERS

audited centers worldwide

96

Number of countries on the continents	
Africa	1
Asia	14
Australia & Oceania	1
Europe	17
North America	2
South America	4
Total	39

Current Event

ACARE
LEVELUP

 **LIVE PRECEPTORSHIPS**

Details

“State of the art management of recurrent angioedema and hands-on training intended for health care professionals from the Arabian Gulf.

ACARE will host a one-day live preceptorship in Abu Dhabi within the ACARE LevelUp program.

This initiative follows the consensus reached on the diagnosis and management of Hereditary Angioedema (HAE) in the Middle East. The goal is to educate healthcare practitioners in the region and promote a unified approach to diagnosing and managing HAE.

The target audience is specialist physicians including Allergists, Dermatologists, Paediatricians, Gastroenterologists and ENTs but also family physicians.

Speakers planned for this event will be some of the KOLs on angioedema including:

- [Marcus Maurer](#),
- [Markus Magerl](#),
- [Mohamed Abuzakouk](#),
- [Iman Nasr](#) and more.

Date:	2nd of February 2024
Location:	Beach Rotana, Abu Dhabi
Topic:	State of the art management of recurrent angioedema and hands-on training intended for health care professionals from the Arabian Gulf

Details

ACARE at GA²LEN UCARE 2023 Conference.

On the morning of the 1st day of the UCARE conference, we invited interested physicians to join us for an ACARE LevelUp Preceptorship.

Past Event

ACARE

LEVELUP

December 7th, 2023
9:00 a.m. – 12:30 p.m. BRT



LIVE PRECEPTORSHIPS

GA²LEN 2023
UCARE
CONFERENCE

December 07-09, 2023
Rebouças Convention Center
Sao Paulo - Brazil

“ Recurrent Angioedema with a special focus on HAE.

Definition, classification, nomenclature and differential diagnosis of recurrent angioedema
Prof. Dr. Markus Magerl, Germany

Diagnostic workup of acquired and hereditary recurrent angioedema
Prof. Dr. Marcus Maurer

Interactive case discussion on how to identify the cause of recurrent angioedema in patients
Prof. Dr. Anete S. Grumach, Dr. Thomas Buttgereit

Treatment of acquired and hereditary angioedema
Prof. Dr. Markus Magerl, Prof. Dr. Marcus Maurer

Must dos in the management of recurrent angioedema
Dr. Thomas Buttgereit, Germany

**The management of hereditary angioedema in South America:
Where do we stand? Where do we go?**
Prof. Dr. Anete S. Grumach, Brazil

29 PARTICIPANTS
FROM
12 COUNTRIES

05/27

Past Event

ACARE
LEVELUP December 9th, 2023

 **LIVE PRECEPTORSHIPS**

GA²LEN 2023
UCARE
CONFERENCE

December 07-09, 2023
Rebouças Convention Center
Sao Paulo - Brazil

Details

ACARE at GA²LEN UCARE 2023 Conference.

On the third day of the conference, Session 9 on December 9th focused on angioedema.

Chairs: Oscar Calderón (PER) | Eli Mansur (BRA)

1. Differential diagnosis of angioedema without hives


- Marta Ferrer (ESP)
- Regis Campos (BRA)

2. Global consensus on the Definition, Acronymus, Nomenclature & Classification of Angioedema (DANCE): new angioedema classification

- Markus Magerl (GER)
- Anete Grumach (BRA)
-

3. Mast cell-driven and non-mast cell-driven angioedema: treatment

- Margarida Gonçalo (POR)
- Henriette Farkas (HUN)



Thank you for everyone who joined us in Brazil!

05/27



Educational Activities

1. ACARE LevelUp Webinar 1
2. Make a Difference Webinars
3. ACARE LevelUp Podcast
4. Journal Club

ACARE LEVELUP WEBINAR 1

HAE CASE REPORTS DISCUSSION: FROM DIAGNOSIS TO TREATMENT

After the great success of our UCARE LevelUp webinars, we are proudly launching ACARE LevelUP webinars in 2024.

The first ACARE LevelUp webinar took place on 31st January 2024, 08:30 – 09:30 am CET.

The following topics and faculty have enriched our webinar:

Introduction and Moderation

Prof. Dr. Ankur Jindal, India (5 min)

The domino effect: unearthing HAE from one-to-many

Dr. Ridhima Aggarwal, India (15 min)

HAE in the East: Addressing disparities in diagnosis and management

Prof. Dr. Philip Li, China (15 min)

A Cautionary Tale

Dr. Hilary Longhurst, New Zealand (15 min)

Q&A

All faculty (10 minutes)

06/27



Educational Activities

1. **ACARE LevelUp Webinar 1**
2. Make a Difference webinars
3. **ACARE LevelUp Podcast**
4. **Journal Club**



MAKE A DIFFERENCE

ACARE Make A Difference is an eleven-part webinar series with a primary focus

ACARE Make A Difference is an eleven-part webinar series with a primary focus on the diagnostic evaluation of patients experiencing recurrent angioedema, including those with hereditary angioedema (HAE), as well as the enhancement of therapy control and optimization. The overarching goal of this webinar series is to facilitate the provision of optimal therapy to all individuals afflicted with recurrent angioedema, particularly those affected by HAE, at the earliest possible stage.

Throughout these webinars, various topics will be explored, including strategies to expedite the diagnosis process and reduce instances of misdiagnosis, methods for family screening in HAE patients, the implementation of closely monitored therapy control measures, and guidance on the continual refinement of therapeutic approaches. This specific webinar will place special emphasis on long-term prophylaxis and treatment optimization based on real world experience.

07/27



Educational Activities

1. ACARE LevelUp Webinar 1
2. Make a Difference Webinars
3. ACARE LevelUp Podcast
4. Journal Club

MAKE A DIFFERENCE 9

ACARE Make A Difference is an eleven-part webinar series with a primary focus

9th of November 2023
17:00 – 18:00 CET

Updated and comprehensive classification and terminology of angioedema.

Introduction 5'

Prof. Dr. Marcus Maurer

Angioedema nomenclature and classification – The need for an update and revision. 15'

Prof. Dr. Markus Magerl

Charité – Universitätsmedizin Berlin Institute of Allergology IFA & Fraunhofer ITMP Immunology and Allergology IA

Finding consensus in angioedemology. 15'

Dr. Thomas Buttgereit

Charité – Universitätsmedizin Berlin Institute of Allergology IFA & Fraunhofer ITMP Immunology and Allergology IA

Unmet needs in angioedema classification. 15'

Prof. Dr. Marcus Maurer

Charité – Universitätsmedizin Berlin Institute of Allergology IFA & Fraunhofer, ITMP Immunology and Allergology, Berlin, Germany

Q&A 10'

All faculty



08/27



Educational Activities

1. ACARE LevelUp Webinar 1
2. Make a Difference Webinars
3. ACARE LevelUp Podcast
4. Journal Club

MAKE A DIFFERENCE 10

ACARE Make A Difference is an eleven-part webinar series with a primary focus

20th of February 2024
17:00 – 18:00 CET



Updated and comprehensive classification and terminology of angioedema.

Introduction 5'

Prof. Dr. Marcus Maurer

Charité – Universitätsmedizin Berlin Institute of Allergology IFA & Fraunhofer ITMP Immunology and Allergology IA, Berlin, Germany

C1-Inhibitor and Long-Term Prophylaxis in real life 15'

Dr. Stefan Cimbollek

Facultativo Especialista de Área en Hospital Universitario Virgen del Rocío, Sevilla, Spain

Lanadelumab and Long-Term Prophylaxis adaption 15'

Prof. Dr. Sorena Kiani-Alikhan

Barts Health NHS Trust, London, United Kingdom

Oral treatments advantages/disadvantages compared to Long-Term Prophylaxis 15'

Dr. Emel Aygören Pursun

Klinik für Kinder- & Jugendmedizin, Universitätsklinikum Frankfurt, Germany

Q&A 10'

All faculty

**REGISTER
HERE**



09/27



Educational Activities

1. ACARE LevelUp Webinar 1
2. Make a Difference Webinars
3. ACARE LevelUp Podcast
4. Journal Club

MAKE A DIFFERENCE 11

ACARE Make A Difference is an eleven-part webinar series with a primary focus

21st of March 2024
17:00 – 18:00 CET

Navigating HAE: A Guide to Effective Patient Management

Introduction 5'

Prof. Dr. Marcus Maurer

Charité – Universitätsmedizin Berlin Institute of Allergology IFA & Fraunhofer ITMP Immunology and Allergology IA, Berlin, Germany

Shared decision making in HAE 15'

Assoc. Prof. Stephen Betschel

Clinical Immunology and Allergy, University of Toronto & St. Michael's Hospital, Toronto, Canada

Effective communication between physician and patient 15'

Dr. Noémi Bara

Policlinica Carit-San Medical, Târgu Mureș, Romania

LTP: How long is long term? 15'

Dr. Marta Ferrer

Clinica Universidad de Navarra, Allergy Department, Pamplona, Spain

Q&A 10'

All faculty

**REGISTER
HERE**





Educational Activities

1. **ACARE LevelUp Webinar 1**
2. **Make a Difference Webinars**
3. **ACARE LevelUp Podcast**
4. **Journal Club**

ACARE LevelUp Podcast

'All Things Angioedema'



ACARE LevelUp Podcast 'All Things Angioedema'

Listen and subscribe to our 'All Things Angioedema' podcast series:



5 Episode 5: **An ENT view of angioedema**

Join Dr Antonia Scherer and Dr Thomas Buttgerit as they discuss the impact of recurrent hereditary angioedema on the larynx. Drawing from her perspective as an ENT expert, Dr Scherer explores how laryngeal angioedema is assessed in the clinic, and the current treatment options available.

6 Episode 6: **Tackling acquired angioedema and related comorbidities**

Join Dr Andrea Zanichelli and Dr Thomas Buttgerit as they discuss complex angioedema cases, including acquired angioedema diagnosed in later life. Drawing from his perspective as Head of the Angioedema Center in Milan, Italy, Dr Zanichelli explores how C1 and C4 inhibitor deficiencies may indicate a possible acquired angioedema diagnosis, common comorbidities due to this condition, and the current treatment options available.

7 Episode 7: **Treating hereditary angioedema**

Join Professor Anna Valerieva and Dr Thomas Buttgerit as they discuss the burden of living with rare forms of angioedema, particularly hereditary angioedema (HAE). Drawing from her expertise as an allergologist at the Medical University of Sofia, Bulgaria, Professor Valerieva emphasises the importance of viewing patients holistically and considering their preferences. The experts also review how the introduction of new treatments has changed patients' lives and minimised recurrent angioedema attacks.

8 Episode 8: **The future of angioedema: Is there a cure on the horizon?**

Join Dr Lauré Fijen and Dr Thomas Buttgerit as they discuss emerging angioedema treatments, covering efficacy, safety, frequency and route of administration. The experts also reflect on the possibility of a cure for hereditary angioedema (HAE)

9 Episode 9: **The AURORA study**

-In the past, they've used 72 different combinations of outcomes and outcome measures." Remy Peterson joins Dr Thomas Buttgerit to discuss the need for the AURORA study, and shares the resulting consensus for acute treatment outcomes in hereditary angioedema (HAE).

11/27

We look forward to your feedback and topic ideas for future episodes. Please use the feedback form [here](#)



Educational Activities

1. ACARE LevelUp Webinar 1
2. Make a Difference Webinars
3. ACARE LevelUp Podcast
4. Journal Club

ACARE LevelUp Podcast

'All Things Angioedema'



ACARE LevelUp Podcast 'All Things Angioedema'

Listen and subscribe to our 'All Things Angioedema' podcast series:



Episode 10: **Who is behind the scenes of ACARE?**

Dr Thomas Buttgerit is joined by Julia Föll and Reinhardt Britz to discuss the responsibilities of working within an ACARE office, covering audit criteria and ongoing ACARE projects.

Episode 11: **The perspective from India in treating paediatric patients**

Dr Thomas Buttgerit is joined by Professor Ankur Kumar Jindal to discuss his experience as a paediatrician treating angioedema in India, covering the reoccurring challenges and how best to counsel families when discussing the risk of transmission to the next generation.

Episode 12: **The HAE specialist: 'Never give up'**

"I want to take an extra step, just to make sure that we never give up and provide them with the care that they deserve to receive." Dr Danny Cohn joins Dr Thomas Buttgerit to talk about the role of an HAE specialist providing long-term, often multigenerational care, including the benefits offered by ACARE centres.

12/27

We look forward to your feedback and topic ideas for future episodes. Please use the feedback form [here](#)



Educational Activities

1. ACARE LevelUp Webinar 1
2. Make a Difference Webinars
3. ACARE LevelUp Podcast
4. Journal Club

ACARE LevelUp Journal Club



If you are a UCARE or ACARE physician and would like to present a paper, please contact Julia Föll at julia.foell@ga2len.berlin or Niklas Mahnke at niklas-amadeus.mahnke@charite.de.

Do you have a Journal Club at your own ACARE center that you would like to open for other UCARE members?

Let us know, we are happy to facilitate this.

The list of possible dates can be found here:

<https://docs.google.com/spreadsheets/d/1O0lv7882xY0KbOxgcsYhBSFoeTqBLamka3dd-INUptk/edit#gid=0>.

Feature

Article by Associate Professor Jason Fok

Professor Jason Fok:

- Allergist/Immunologist
- Box Hill Hospital, Melbourne, Australia.
- Monash Medical Centre, Melbourne, Australia



Hot topics in angioedema



Treatment landscape in hereditary angioedema (HAE) is rapidly evolving, largely due to improved understanding of disease pathomechanism in recent years. We have come a long way since the first recognition of the hereditary nature of “angioneurotic oedema” by Sir William Osler in 1888 regarding a case of fatal asphyxiation. Further dissection into the biochemical basis of HAE regarding C1 inhibitor deficiency by Donaldson and Evans in 1963 has laid the foundation for future understanding of disease pathophysiology and therapeutic discoveries.

Current treatment strategies for HAE type 1 and type 2 involve acute attack management, short term prophylaxis (prior to a procedure) and long-term prophylaxis. Long-term prophylaxis aims to achieve complete control of disease and improve quality of life.

Icatibant, a bradykinin B2 receptor antagonist, is an on-demand medication indicated in acute attacks. C1 inhibitor replacement has a strong role in short term and long-term prophylaxis. Lanadelumab is a long-acting kallikrein inhibitor administered subcutaneously. Berotralstat is a plasma kallikrein inhibitor given orally which inhibits proteolytic activity. Attenuated androgens such as danazol increase liver synthesis of C1 inhibitor protein from the remaining normal C1 gene. Tranexamic acid is an antifibrinolytic agent that reduces activation of plasminogen into plasmin, resulting in reduced bradykinin production.

Feature

Article by Associate Professor Jason Fok

Professor Jason Fok:

- Allergist/Immunologist
- Box Hill Hospital, Melbourne, Australia.
- Monash Medical Centre, Melbourne, Australia

Hot topics in angioedema



Access and availability of the medications discussed above vary greatly across different geographical regions.

There are a number of new medications being developed in the space of HAE.

Garadacimab is a monoclonal antibody given subcutaneously once monthly that inhibits activated factor XII (FXIIa). Its efficacy and safety profile have been demonstrated in a recent multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (the VANGUARD study).

Donidalorsen is an antisense inhibitor of prekallikrein that was demonstrated to reduce HAE attack frequency and improve patient quality-of-life in a randomised phase 2 study. More recently, a 2-year interim analysis of the phase 2 open-label extension study showed that mean monthly attack rate was 96% lower than the study run-in baseline rate. There was also improvement in Angioedema Quality of Life Questionnaire total scores. No new safety concerns were noted.

There are several other new medications currently being explored and assessed, including gene therapy. Many of these are still in phase 1 trial, so watch the space!

Feature

By Dr. Ankur Jindal and Prof. Sunil Dogra

Dr. Ankur Jindal:

- Assistant Professor of Pediatric Clinical Immunology and Rheumatology, Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh (India)
- Secretary General, Hereditary Angioedema Society of India (HAESI)



Prof. Sunil Dogra:

- Professor, Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh (India)
- President General, Hereditary Angioedema Society of India (HAESI)



Progress and lessons learned

March 9, 2019 was the beginning of a new chapter in the history of hereditary angioedema in India. HAE International (HAEi) organized a physician-doctor meeting in New Delhi.

This was led by Ms. Fiona Wardman (HAE International) and Dr. Shaibal Guha (HAE India). There were discussions about HAE in general and challenges with this disease in India (none of the first line treatment options for HAE were available in India at this time). But the most important aspect of this meeting was that India finally started talking about HAE. We could realise the potential of making difference to the lives of people living with HAE in India and then we never looked back.

On **February 9, 2020** [the second and final day of the 3rd Asia Pacific Society for Immunodeficiencies (APSID) Congress held at Chandigarh, India], there was a 1½ hour session on HAE. This was probably for the first time that there was a separate session on HAE in any immunodeficiency conference. The session was led by Dr. Hilary Longhurst and Ms. Fiona Wardman.

On **April 6, 2020**, we received an email communication from Ms. Fiona Wardman. It said “I thought I would send you some information on the ACARE centres as I believe that you and PGIMER would be a great centre in India.” On July 3, 2020, the Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh was designated as Angioedema Center of Reference and Excellence.

As has rightly been said, ‘Success is a journey of countless baby steps’. We knew that what we had done so far was not enough; we still had none of the first line treatment options for HAE in India.

On **February 5, 2021**, the HAE Society of India was established at Chandigarh with an aim to increase awareness and to promote knowledge about HAE amongst physicians, to improve quality of life of patients and bring better treatment options in India.

In our endeavour to increase awareness about HAE in India, we decided to organize at least one national conference every year. We organized our first conference (virtual) on **May 16, 2021**. This was attended by more than 300 delegates across the country. Dr. Hilary Longhurst (New Zealand) and Ms. Fiona Wardman (Sydney, Australia) were the guest faculty for the conference.

Hereditary angioedema in India:

Progress and lessons learned

The society organized the 2nd National conference on May 15, 2022 (in-person) and 3rd National conference on **May 27-28, 2022** (in-person).


1st National Conference of HAE Society of India



2nd National Conference of HAE Society of India



2nd National Conference of HAE Society of India



Hereditary angioedema in India:

Progress and lessons learned

With the help of the ACARE office at Berlin, we organized an ACARE preceptorship on recurrent angioedema on **February 4-5, 2023** (Delegates from India and Kazakhstan)

ACARE preceptorship on recurrent angioedema



In addition, we organized small CMEs in different parts of the country to improve awareness about HAE amongst physicians in India.

The awareness of HAE in India is gradually improving now, increasing number of patients are being identified and more centres have now started diagnosing and managing patients with HAE. However, we are still seeing the 'tip of the iceberg'. Because we have not yet been able to diagnose more than 1% of all patients with HAE in India (the current best estimate for number of patients with HAE in India is 27,000 – 135,000 patients).

Plasma derived C1-inhibitor concentrate was first marketed in India in August 2022. We now have 3 different firms who have started marketing plasma derived C1-inhibitor concentrate.

A rather big step in this journey came in October 2023 when all patients with HAE in India became eligible to access on demand treatment through the National Rare Disease Policy (NRPD) of Government of India.

Feature

HAEi and You! by Rachel Annals

About Rachel Annals:

Rachel Annals is the Coordinator, Global Advocacy and ACARE, at HAE International (HAEi). ACARE is an equal partnership between HAEi and GA2LEN, which aims to develop and accredit centres of excellence around the world for patients with angioedema.



HAEi

HAE International is a global non-profit network of member organizations dedicated to raising awareness of hereditary angioedema (HAE) and improving the lives of people with HAE. Established in 2003, with the support of the late Professor Marco Cicardi, HAEi is now a registered non-profit corporation, which presently boasts a network of 99 member organizations, and are continually welcoming new countries into the fold.

HAEi is a group of compassionate HAE patients and care givers who have firsthand experience of HAE and whose mission revolves around dedicating their lives to increasing public knowledge about HAE, reducing the time it takes to diagnose the condition, and passionately advocating for the approval and accessibility of life-saving treatments for all those who endure the challenges of living with the condition. They are also dedicated to enabling individuals residing in more remote areas to gain access to a specialist center, vital HAE testing, and treatment options, consequently enhancing their quality of life.

HAEi and GA2LEN share many objectives, including increased education about HAE. The ACARE centers work closely with HAEi and their member organizations to further enhance the quality and consistency of clinical care and create a robust environment for local and global HAE research.

Feature

HAEi and You! by Rachel Annals

About Rachel Annals:

Rachel Annals is the Coordinator, Global Advocacy and ACARE, at HAE International (HAEi). ACARE is an equal partnership between HAEi and GA²LEN, which aims to develop and accredit centres of excellence around the world for patients with angioedema.



Rachel's role as Coordinator, will strengthen the relationship **between HAEi and GA²LEN** and will ensure information is shared efficiently, disseminating updates, news, and opportunities and resources to help actively engage ACARE centers and members.

By bringing together the largest network of specialists dedicated to treating angioedema globally, and HAEi, we can do even more to reach and support people with HAE across the globe.

Rebekka Locke (ACARE), Rachel Annals (HAEi), Michal Rutkowski (HAEi), Fiona Wardman (HAEi), Reinhardt Britz (ACARE) and Julia Föll (ACARE) on **November 30 in Berlin**.



More informations about our partner HAEi click here




Feature

HAEi TrackR

About TrackR:

HAE TrackR allows the patient to download a comprehensive report of their treatments (preventative and on-demand) and attacks to be used as a tool for them and their physician.



Since July 2023, HAE TrackR also has added the following features:

- reminder function to help the patient remember to take their medication
- improved reporting
- better documentation
- personalized treatment plan
- clinical trials feature

Why wait?

Take control of your HAE today
-by downloading HAE TrackR,
HAEi's free electronic diary

AVAILABLE IN

36
LANGUAGES



Current Scientific Projects

1. [SHAERPA](#)
2. [IMAGINE 2.0](#)
3. [CARE](#)
4. [HAPY](#)
5. [10 questions \(that can save lives\)](#)

Details

We need YOUR participation!

[SHAERPA](#)

Stopping androgen treatment in patients with HAE – characterization of reasons and protocols and development of advice for patients and physicians.

For project-related documents, please see our member area or contact the project lead: carolina.vera@charite.de

[IMAGINE 2.0](#)

Identification of mutations in genes of patients with recurrent idiopathic and hereditary angioedema.

For project-related documents, please see our member area or contact the project lead: thomas.buttgereit@charite.de

[Chronic Angioedema Registry CARE](#)

If you have any questions, please do not hesitate to contact the **CARE Office**. You are also welcome to visit the **CARE Homepage**, which is continuously growing and will soon provide all the important information and documents.

To all ACARES: Please spread the word, since all angioedema treating physicians are highly welcome to participate and to contribute to this important project. Let's bring our combined efforts together towards improving treatment and positively impacting the lives of those affected by angioedema.

Current Scientific Projects

1. [SHAERPA](#)
2. [IMAGINE 2.0](#)
3. [CARE](#)
4. [HAPY](#)
5. [10 questions \(that can save lives\)](#)

Details

We need YOUR participation!

[HAPY](#) (recruitment ongoing)

Hereditary Angioedema in Pregnancy

A questionnaire for patients with HAE and their physicians will be used to retrospectively collect and evaluate details on the influence of pregnancy on HAE. The time period surveyed will cover the periods before, during and after the pregnancies/breastfeeding periods and should include, among other things, disease activity, medication, contraception, concomitant diseases and outcome of the pregnancies.

Update: The project parameters have just been changed:

1. The pregnancy can now be any length of time ago, not just up to three years ago.
2. The physician no longer has to sign the consent form. It has now become an anonymous survey.

Please share this survey with your HAE patients who have been pregnant in the past.

For project-related documents, please see our member area or contact the project lead:

thomas.buttgereit@charite.de

[10 questions](#) (that can save lives)

10 questions can help you determine the exact cause and find the correct treatment. You can find the questionnaire under the Resources tab, or just click [here](#).

So far, the ACARE 10 questions tool is available in 14 languages (**English, German, Czech, Chinese, Turkish, Russian, Spanish, Portuguese, French, Arabic, Italian, Greek, Persian, Lithuanian**).

Would you like to help us translate this important tool into your language? Reach out to [Felix Aulenbacher](#) or [Julia Föll](#), we would love to have you on board.

Please share 10 questions with your patients, patient organizations in your region and your colleagues. Feel free to link the **ACARE 10 questions tool** from your ACARE center, patient organization or personal website, but make sure to credit ACARE and include ACARE branding.



Sharing is Caring

Please share our news with your network as well, and as always, we look forward to your feedback, ideas, and engagement.

For more up to date ACARE info, please see our website or view our [social media channels](#).



If **YOU** would like to share something with the network in the next **newsletter**, please be in touch!



Things to say

A special thank you to

Jason Fok, Ankur Jindal, Sunil Dogra and Rachel Annals for their contributions.

The ACARE Office wishes you all

a happy healthy and successful 2024!



Sponsors

Thanks

We would like to thank the ACARE LevelUp Sponsors:

Platinum

Takeda



Silver

Biocryst



Bronze

Kalvista

